HeartGenetics, member of the IST Spin-off community, was distinguished by Glintt. The project “MyPharmaGenes” was one of the 4 winners of the HINTT Awards –Digital Maturity, and stood out among 10 finalists.

The MyPharmaGenes genetic test, which is performed from a sample of oral mucosa, is a unique tool that guarantees a personalized and effective therapy with a reduction of side effects and toxicity, thus playing an important role in the implementation of personalized medicine. This innovative and unique genetic test in Europe arrived on the market in July this year and provides the doctor and the citizen with the necessary information on how the organism responds to various drugs in 5 therapeutic areas (Psychiatry, Pain Management, Cancer, Diabetes and Cardiovascular disease).

An app was also developed to help users whenever they buy a medicine.

Created in 2013, HeartGenetics is a startup company that has developed genetic testing in the cardiovascular field. The company main goal is to play a key role in applied genetic knowledge and genetic testing, going into the wellness space.